ImmunityBio, Inc. (IBRX) Tops Q4 EPS by 8c

ImmunityBio, Inc. (NASDAQ: IBRX) reported Q4 EPS of ($0.09), $0.08 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $7.2 million versus the consensus estimate of $6.16 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.

You May Also Be Interested In

• Lyft to acquire Serveo's bikeshare business in Spain
• Top 10 investors bought 75% of Rivian's $1.2B share offering - report
• Trump on Iran: may be a big attack, may take Kharg, may put back blockade